Abstract:  Abstract　Objective: To compare the therapeutic efficacy of non-surgical treatments for advanced pancreatic cancer. Methods: Data of 206 patients with advanced pancreatic cancer treated from April 2004 to October 2010 were examined in this retrospective study. Results: The response rates to the various treatment options were 37.18% for stereotactic radiosurgery, 21.43% for high-intensity focused ultrasound, 26.67% for chemotherapy, 79.31% for stereotactic radiotherapy plus chemotherapy, and 61.53% for high-intensity focused ultrasound plus chemotherapy. The clinical efficacy of combination therapy was superior to that of any single treatment ( P < 0.05). Clinical benefit response ( CBR ) rates were 48.71%, 88.09%, 30.00%, 82.76% and 85.19%, respectively. High-intensity focused ultrasound therapy was superior to stereotactic radiation ( P < 0.01 ), while the clinical benefit of combination therapy was significantly better than the benefits observed following single stereotactic radiotherapy or chemotherapy ( P < 0.01 ). The rate of toxic side effects were the lowest in the group treated by high-intensity focused ultrasound therapy ( P < 0.01 ) and was the highest in patients treated by stereotactic radiotherapy plus chemotherapy ( P < 0.01 ). There were no significant differences among the other groups ( P > 0.05 ). The median survival was 10.6, 7.6, 6.9, 15.3, and 13.6 months, respectively. The survival of the patients receiving the combination therapies was longer than the survival of patients treated by monotherapy ( P < 0.05 ), and the patients in the combination stereotactic radiotherapy plus chemotherapy group exhibited the longest survival ( P < 0.05 ). Conclusion: Stereotactic radiation therapy, high-intensity focused ultrasound, and chemotherapy were all effective treatments for patients with advanced pancreatic cancer. The efficacy of combined therapy was superior to any single treatment alone. Side effects of the high-intensity focused ultrasound therapy were low and this option was particularly suitable for palliative treatment of patients with poor health status. In patients with better health status, stereotactic radiation therapy plus chemotherapy was the most effective treatment choice.